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vascularization was found to be signifi cantly compro-
mised when compared with wild-type control animals 
which showed profound neovascularization within the 
granulation tissue during the wound healing process. 
Thus, PMN infi ltration seems to facilitate infl ammation-
mediated angiogenesis which may be a consequence of 
the broad spectrum of proangiogenic factors expressed 
by these cells. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Human polymorphonuclear neutrophils (PMN) are 
well known to play an important role in host defense and 
infl ammation. During the acute infl ammatory response, 
the PMN extravasate from the blood into the tissue, 
where they exert their defense functions. However, grow-
ing evidence supports the concept that PMN also contrib-
ute to infl ammation-mediated angiogenesis, which is a 
critical step in the process of wound healing and repair. 
PMN secrete a variety of soluble mediators, including 
interleukin 8 (IL-8)  [1] . IL-8 is an important proinfl am-
matory mediator  [2] , but as well as other cytokines, it is 
also able to induce angiogenesis  [3] . In addition, PMN 
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 Abstract 
 Growing evidence supports the concept that polymor-
phonuclear neutrophils (PMN) are critically involved in 
infl ammation-mediated angiogenesis which is impor-
tant for wound healing and repair. We employed an oli-
gonucleotide microarray technique to gain further in-
sight into the molecular mechanisms underlying the 
proangiogenic potential of human PMN. In addition to 
18 known angiogenesis-relevant genes, we detected the 
expression of 10 novel genes, namely midkine, erb-B2, 
ets-1, transforming growth factor receptor-  2  and -  3 , 
thrombospondin, tissue inhibitor of metalloproteinase 2, 
ephrin A2, ephrin B2 and restin in human PMN freshly 
isolated from the circulation. Gene expression was con-
fi rmed by the RT-PCR technique. In vivo evidence for the 
role of PMN in neovascularization was provided by 
studying neovascularization in a skin model of wound 
healing using CD18-defi cient mice which lack PMN infi l-
tration to sites of lesion. In CD18-defi cient animals, neo-
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secrete the proangiogenic hepatocyte growth factor  [4, 5] 
and the vascular endothelial growth factor (VEGF)  [6] , 
one of the most important activators of angiogenesis  [7] . 
As PMN accumulate in high number at sites of lesion, 
their ability to release different proangiogenic mediators 
suggests a putative role of PMN in infl ammation-medi-
ated angiogenesis. 
 In vivo evidence for the role of PMN in infl ammation-
mediated angiogenesis and wound repair was provided 
by the observation that CXCR2-defi cient mice, which 
lacked PMN infi ltration in the thioglycollate-induced 
peritonitis  [8] , showed delayed angiogenesis and, more-
over, impaired cutaneous wound healing  [9] . IL-8 is 
known to bind to CXCR2 on endothelial cells and to in-
duce angiogenesis  [10] . In vivo, PMN represent the main 
source of macrophage infl ammatory protein 2, the mu-
rine homolog of human IL-8  [11] . Accordingly, a recent 
study has demonstrated a role of macrophage infl amma-
tory protein 2 and VEGF in PMN-mediated angiogenesis 
in mice  [12] . 
 Further evidence for the involvement of PMN in IL-
8-mediated angiogenesis was obtained in a study demon-
strating that the angiogenic response upon IL-8 treatment 
was absent in neutropenic animals  [13] . Thus, the linkage 
of infl ammation, angiogenesis and wound healing may at 
least in part result from the multifunctional role of pro-
infl ammatory cytokines, e.g. IL-8. However, tumor ne-
crosis factor (TNF)-  , which is released by PMN upon 
activation  [14] , seems to represent another factor that is 
involved in PMN-mediated angiogenesis. TNF-  has 
been shown to induce IL-8, VEGF and basic fi broblast 
growth factor expression in microvascular endothelial 
cells and neutralizing antibodies against IL-8, and VEGF 
blocked TNF-  -induced neovascularization  [15] . More-
over, we have recently shown that the conditioned media 
derived from activated human PMN induced the sprout-
ing of capillary-like structures in vitro  [16] , showing that 
human PMN have the ability to directly induce angiogen-
esis. Thus, accumulating evidence demonstrated an im-
portant role of PMN in angiogenesis, but the full spec-
trum of PMN-derived proangiogenic factors remained 
elusive. Therefore, we employed the microarray tech-
nique to delineate the full molecular basis of the proan-
giogenic potential of human PMN. The impact of PMN 
in infl ammation-mediated angiogenesis was studied in a 
skin model of wound healing using CD18-defi cient ani-
mals which lack PMN infi ltration to sites of lesion due to 
the absence of leukocyte adhesion molecules of the   2 -
integrin family (CD11/CD18)  [17] . 
 Materials and Methods 
 Reagents 
 Phosphate-buffered saline (PBS) was obtained from Biochrom, 
Berlin, Germany, agarose was provided by GibcoBRL, Eggenstein, 
Germany, and DNA markers (100-bp DNA ladder) were obtained 
from MBI Fermentas, St. Leon-Rot, Germany. Glucose and Percoll 
were obtained from Sigma, Deisenhofen, Germany, Liquemin 
2500 (heparin) was purchased from Hoffmann-La Roche, Grenz-
ach-Wyhlen, Germany, and all other reagents and chemicals were 
 Table 1. Supplementary data showing the relative expression of 
angiogenesis-relevant genes in human PMN 
Gene Relative gene expression
microarray lot 1906 microarray lot 0507
array 1 array 2 array 3 array 4
uPA n.d. 0.02 0.32 0.23
erb-B21 0.08 0.05 0.42 0.33
TRI 0.03 n.d. 0.36 0.31
TGF-1 0.14 0.08 0.35 0.42
TIMP-1 0.10 n.d. 0.34 0.35
VEGF n.d. 0.06 0.33 0.41
Ephrin A21 0.10 n.d. 0.45 0.33
Ephrin B21 0.08 n.d. 0.46 0.35
3-Integrin subunit n.d. 0.31 n.d. 0.30
GRO- 0.27 0.29 0.43 0.27
CHGA 0.20 0.42 0.42 0.31
THBS-31 n.d. 0.31 n.d. 0.39
TGF- 0.24 n.d. 0.44 0.42
TIMP-21 0.31 0.14 0.70 0.35
Restin1 0.27 0.36 0.43 0.49
VE-cadherin1 0.32 0.57 0.43 0.29
MMP-9 0.27 0.16 0.68 0.52
PECAM-1 0.52 0.18 0.50 0.53
ets-11 n.d. 0.49 n.d. 0.39
HIF-1 0.63 0.42 0.68 0.36
TNF- 0.31 0.37 1.10 0.39
TRII1 0.37 n.d. 0.93 0.35
Cox-2 0.86 0.30 0.71 0.41
MDK1 0.48 0.34 1.03 0.44
5-Integrin subunit 0.28 n.d. 0.97 n.d.
HPSE 0.39 0.25 1.44 0.43
IL-8 1.76 0.91 1.95 0.50
TRIII1 2.55 0.54 1.59 0.45
Gene expression was measured using the oligonucleotide micro-
array technique (GEarray kit for angiogenesis-relevant genes, cata-
logue number HS-009N-4; SuperArray) in human PMN freshly iso-
lated from the circulation. Microarrays with two different lot num-
bers were used. Gene expression normalized for the expression of 
-actin. Data represent relative OD measured in PMN from 4 dif-
ferent individuals. n.d. = Not detected.
1 Genes previously unknown to be expressed in PMN.
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purchased from Merck, Darmstadt, Germany, and Serva, Heidel-
berg, Germany. 
 Isolation of Human PMN 
 PMN were isolated from heparinized blood (10 IU/ml) of 
healthy adult volunteers, according to the institutional guidelines 
of the Ludwig Maximilians University, Munich, Germany. After 
erythrocyte sedimentation in the presence of 40% (v/v) autologous 
plasma for 1 h, the leukocyte-rich plasma was layered onto a dis-
continuous Percoll gradient as previously described  [18] and cen-
trifuged at 600  g for 20 min. The PMN-containing layer was col-
lected and washed in Dulbecco’s PBS. PMN viability was  1 99%, 
as assessed by the trypan blue exclusion test; purity was  1 99%, as 
analyzed by microscopy using Haemacolor staining (Merck). 
 Gene Array 
 The human GEarray kit for angiogenesis-relevant genes (cata-
logue number HS-009N-4, lot numbers 1906 and 0507; SuperAr-
ray, Bethesda, Md., USA) was used to characterize the gene expres-
sion profi les of human neutrophils freshly isolated from the circula-
tion of 4 different donors (the complete gene list can be obtained 
on the Internet at http://www.superarray.com). Total RNA was iso-
lated from the neutrophils by the guanidine isothiocyanate method 
 [19] using TRI Reagent (Sigma). The array was performed accord-
ing to the manufacturer’s instructions. Briefl y, probe synthesis was 
performed for 120 min at 42  °  C using RNA (3   g) and 100 U re-
verse transcriptase (Promega, Madison, Wisc., USA), 8 U RNase 
inhibitor (Promega), a dNTP mix with biotin-16-dUTP (Roche 
Molecular Biochemicals, Penzberg, Germany) and a primer mix. 
After prehybridization for 1 h at 60  °  C with GEAhyb hybridization 
solution containing 100   g/ml heat-denatured salmon sperm DNA 
(Stratagene, La Jolla, Calif., USA), the fi lters were hybridized over-
night at 60  °  C with the heat-denatured biotinylated cDNA probes. 
After two extensive washes, the fi lters were incubated with alkaline 
phosphatase-conjugated streptavidin and gene expression was de-
tected by chemiluminescence using the alkaline phosphatase sub-
strate CDP-Star and exposure to X-ray fi lms (XOMAT-AR, Kodak, 
Germany). Data were analyzed using the GEarray Analyzer pro-
gram (http://www.superarray.com). A blank was used for back-
ground subtraction, and data were normalized using   -actin expres-
sion. The relative gene expression is shown in the supplementary 
data ( table 1 ,  fi g. 1 ). The data were obtained from microarrays with 
two different lot numbers. Gene expression was defi ned ‘positive’ 
when detected by microrrays from both lot numbers in at least 2 of 
4 individuals tested. 
 Reverse Transcription and Polymerase Chain Reaction 
 The expression of genes that was found to be positive using the 
microarray technique was verifi ed by RT-PCR analysis. Total RNA 
was isolated from human PMN as described above. Subsequently, 
RNA (2   g) was reverse transcribed into cDNA using oligo(dT) 15  
primers (Promega, Mannheim, Germany) and 200 U reverse tran-
scriptase Moloney murine leukemia virus (Promega). PCR amplifi -
cation was carried out using specifi c primer sets (Metabion, Munich, 
Germany) ( table 2 ) and 0.25 U Taq DNA polymerase (Promega). 
PCR products were analyzed by agarose gel electrophoresis and vi-
sualized with ethidium bromide under UV light. For each gene, the 
RT-PCR was carried out using PMN obtained from at least 3 dif-
ferent individuals. With the exception of vascular/endothelial (VE)-
cadherin, the RT-PCR for all genes that were defi ned ‘positive’ by 
microarray analysis gave a positive result with all donors tested. For 
VE-cadherin, all donors showed a negative result in the RT-PCR. 
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 Fig. 1. Genes previously unknown to be ex-
pressed in PMN are indicated by black bars. 
Gene expression was defi ned ‘positive’ 
when detected by microarrays from both lot 
numbers in at least 2 of 4 different indi-
viduals tested. The obtained data were nor-
malized using the expression of   -actin. 
Data represent mean relative OD  8 SD. 
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 Mice 
 CD18–/– homozygotes  [17] and CD18+/+ wild-type controls 
were derived from heterozygote crosses on a mixed 129Sv  ! 
C57BL/6 background. Animals were constantly maintained under 
specifi c pathogen-free conditions. Wound healing studies were per-
formed using mice at the age of 8–12 weeks. All experiments were 
institutionally approved and done in accordance with the German 
Law for Welfare of Laboratory Animals. 
 Wound Healing Model 
 Prior to injury, mice were anaesthetized by intraperitoneal in-
jection of a solution (250   l/25 g body weight) containing ketamine 
(10 g/l) and xylazine (8 g/l). After shaving the dorsal hair and clean-
ing the exposed skin with 70% ethanol, full thickness (including the 
panniculus carnosus) excisional wounds were punched at two sites 
in the middle of the dorsum using 5-mm biopsy stamps (Stiefel, 
Offenbach, Germany). Wounds were left uncovered and were ex-
cised 5 days after induction of injury. For the preparation of cryo-
 Table 2. Specifi c primer sets 
Gene Primer Product, bp PCR
-Actin u: TGTCCACCTTCCAGCAGATGTG
d: AGTCCTCGGCCACATTGTGAAC
300 21 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
Ephrin A2 u: GCGTGAAGAGCTGGAAC
d: TACGCCGTCTACTGGAAC
294 40 cycles: 60 s 94° C, 60 s 55° C, 60 s 72° C 
Ephrin B2 u: GAAGGGACTCCGTGTGGAAG
d: CTGGTTTGGCACAGTTGAGG
303 11 cycles: 60 s 94° C, 120 s increment 59–64° C, 60 s 72° C 
31 cycles: 60 s 94° C, 60 s 60° C, 60 s 72° C
erb-B2 u: GGAAGTACACGATGCGGAGA
d: GCCATCACGTATGCTTCGTC
277 35 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
ets-1 u: GAATGACTACCCCTCGGTCA
d: TTGGTCCACTGCCTGTGTAG
398 25 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
HIF-1 u: TCCTTCTCTTCTCCGCGTGT
d: GTGGCAACTGATGAGCAAGC
231 26 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
MDK u: AATGCTCAGTGCCAGGAGAC
d: AGCTTCCCAGAATCCCTTGT
299 40 cycles: 60 s 94° C, 60 s 61° C, 60 s 72° C
Restin u: TCTTGGGGAGACCGACTTTG
d: TGCTGCTGCTTCTCCTTCAG
399 32 cycles: 60 s 94° C, 60 s 60° C, 60 s 72° C
TRII u: CCTAACCTGCTGCCTGTGTG
d: CGTTGTCCTTCATGCTTTCG
302 32 cycles: 60 s 94° C, 60 s 60° C, 60 s 72° C
TRIII u: AGTGTGTGCCTCCTGACGAA
d: ACTTGCTGCCTTCCTGCTGT
298 28 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
THBS-3 u: GGCTGTGACCCAAACTCCAT
d: TTCTTGATCCCATCCCCATC
401 11 cycles: 60 s 94° C, 120 s increment 55–60° C, 60 s 72° C 
28 cycles 60 s 94° C, 60 s 58° C, 60 s 72° C
TIMP-2 u: CTCGGCAGTGTGTGGGGTC
d: CGAGAAACTCCTGCTTGGGG
364 25 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
VE-cadherin1 u: ACCGGATGACCAAGTACAGC
d: ACACACTTTGGGCTGGTAGG
596 35 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
VE-cadherin2 u: ACGAAAAGCTTGGACCGAGA
d: TCAATGGTGAAAGCGTCCTG
293 35 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
VE-cadherin3 u: ATGCTCCTCGCCACATC
d: ACAACCGATGCGTGAAC
450 35 cycles: 60 s 94° C, 60 s 59° C, 60 s 72° C
The specifi c primer sets were used at a fi nal concentration of 0.2 M each. PCR cycles were followed by incubation for 5 min at 72° C 
for elongation of PCR products. Increment: annealing was performed with an increment of 0.5° C per cycle. u = Upstream primer; d = 
downstream primer. For the detection of the VE-cadherin mRNA, three different primer sets for VE-cadherin1–3 were used which all 
gave negative results. 
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sections, wounds were embedded in Tissue-Tek OCT ®  compound 
(Fisher Scientifi c, Bridgewater, N.J., USA) and immediately frozen 
in liquid nitrogen. 
 Immunofl uorescence Histology 
 Methanol-fi xed frozen sections (5   m) from the middle of the 
wound were incubated for 1 h with the rat anti-mouse CD31 anti-
body (BD Biosciences Pharmingen/BD Bioscience, Heidelberg, 
Germany) in PBS containing 1% BSA. After three washes for 10 
min in PBS, sections were incubated for 1 h with the secondary 
cyanine 2-conjugated anti-rat antibody (Dianova, Hamburg, Ger-
many), washed again, mounted with Mowiol (Dako, Hamburg, 
Germany) and analyzed by fl uorescence microscopy using an Ax-
ioscop 2 microscope (Zeiss, Oberkochen, Germany) supported by 
AxioVison ®  software (Zeiss). 
 Statistical Analysis 
 Statistical signifi cance was determined using the Mann-Whit-
ney U test. Differences were considered to be statistically signifi -
cant at values of p  ! 0.005. 
 Results 
 In order to elucidate the molecular basis for the pro-
angiogenic potential of human PMN, we used an oligo-
nucleotide microarray technique to identify angiogene-
sis-relevant genes in these cells. Using this approach, we 
screened 96 angiogenesis-relevant genes in human PMN, 
freshly isolated from the circulation. We detected the ex-
pression of 28 genes. As shown in detail in  table 3 , these 
genes include different cytokines, namely IL-8, growth-
related oncogene-alpha (GRO-  ), midkine (MDK), trans-
forming growth factor-  1  (TGF-  1 ), TNF-  and VEGF. 
Whereas IL-8, GRO-  , TGF-  1 , TNF-  and VEGF are 
well known to be expressed in human PMN, this was the 
fi rst demonstration of MDK expression. Therefore, we 
employed the RT-PCR technique to verify this result
( fi g. 2 ). Using this approach, we were able to detect MDK 
at the RNA level confi rming the expression of this novel 
chemokine in human PMN. 
 In addition, the microarray technique revealed the 
mRNA expression of three angiogenesis-relevant tran-
scription factors in human PMN, namely erb-B2, ets-1 
and hypoxia-inducible factor 1 alpha (HIF-1  ). Whereas 
human PMN were already known to express HIF-1  , this 
was the fi rst description for erb-B2 and ets-1 expression 
in human PMN. Subsequently, we were able to confi rm 
this result by the RT-PCR technique ( fi g. 2 ). Among the 
cell surface receptors, we showed that human PMN not 
only express the TGF-  type I receptor (T  RI), but also 
the TGF-  type II (T  RII) and type III receptors (T  RIII). 
These observations were confi rmed by the RT-PCR tech-
nique. Furthermore, we detected the expression of the 
known adhesion molecules CD49e, CD61, CD31 and 
thrombospondin (THBS)-1 in human PMN. However, 
the expression of the unknown genes THBS-3 and VE-
cadherin was also detectable by means of the microarray 
technique. We were able to confi rm the expression of 
THBS-3 by means of the RT-PCR technique. However, 
 Table 3. Angiogenesis-relevant genes expressed in freshly isolated 
PMN as delineated by the microarray technique 
Gene Other names Reference
Cytokines
IL-8 CXCL8 1
GRO- CXCL1 20
MDK1 neurite growth-promoting
factor 2
TGF-1 21
TNF- 14
VEGF 6
Transcription factors
erb-B21 neu, HER-2
ets-11
HIF-1 30
Cytokine receptors
TRI 39
TRII1
TRIII1
Adhesion molecules
5-Integrin subunit CD49e 44
3-Integrin subunit CD61 45
PECAM-1 CD31 46
THBS-1 47
THBS-31
VE-cadherin1
Enzymes
Cox-2 49
HPSE 50
MMP-9 gelatinase, type V collagenase 34
uPA urokinase 38
Others
CHGA 53
Ephrin A21
Ephrin B21
Restin1 cytoplasmic linker
protein 170
TIMP-1 56
TIMP-21
1 Genes previously unknown to be expressed in PMN. The re-
sults are representative of three independent experiments.
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we were unable to demonstrate VE-cadherin expression 
in PMN using this approach, although three different 
primer sets were used and positive results were obtained 
from human umbilical vein endothelial cells indicating 
that the primer sets were functional. This suggests that 
the microarray gave a false-positive result in the case of 
VE-cadherin. 
 Moreover, we confi rmed the expression of four well-
known angiogenesis-relevant enzymes, namely cyclooxi-
genase 2 (Cox-2), heparanase (HPSE), matrix metallopro-
teinase (MMP)-9 and the urokinase-type plasminogen 
activator (uPA) in human PMN by the microarray tech-
nique. Furthermore, we detected the expression of the 
known angiogenesis-relevant genes tissue inhibitor of me-
talloproteinase (TIMP)-1 and chromagranin A (CHGA) 
in human PMN. In addition, we found the expression of 
four novel genes in human PMN, i.e. TIMP-2, ephrin A2, 
ephrin B2 and restin using the microarray technique, and 
we were able to confi rm this fi nding by the RT-PCR tech-
nique ( fi g. 2 ). Taken together, we detected a total of 28 
angiogenesis-relevant genes in human PMN including 11 
novel genes by the microarray technique, namely MDK, 
erb-B2, ets-1, T  RII, T  RIII, THBS-3, VE-cadherin, 
ephrin A2, ephrin B2, restin and TIMP-2. With the ex-
ception of VE-cadherin, we were able to confi rm the ex-
pression of all genes at the RNA level using the RT-PCR 
technique. 
 In order to study the impact of PMN for infl amma-
tion-mediated angiogenesis, neovascularization was stud-
ied in a skin model of wound healing using CD18–/– mice 
and wild-type control animals. As CD18–/– mice lack the 
expression of   2 -integrins (CD11/CD18), which are crit-
ical for PMN extravasation, the CD18–/– mice show vir-
tually no PMN infi ltration to sites of skin lesion, whereas 
wild-type animals demonstrate a robust PMN infi ltration 
of wounded skin  [17] . At day 5 after the induction of in-
jury, we measured neovascularization in the wound beds 
using CD31 staining of blood vessels and detected a pro-
found neovascularization in the granulation tissue of 
wild-type animals which is well known to be typical and 
important for the normal wound healing process ( fi g. 3 a). 
In contrast, CD18–/– animals that lack PMN infi ltration 
to sites of wounded skin showed a severely diminished 
vessel density within the granulation tissue at the same 
time point. This result was confi rmed by counting the 
vessels under the microscope ( fi g. 3 b). The median num-
ber of CD31-positive vessels per high-power fi eld was 159 
(range 114–185) in wound beds of wild-type animals and 
105 (range 0–148) in CD18–/– animals (p  ! 0.005). Thus, 
the absence of profound PMN infi ltration during the 
 Fig. 2. Novel angiogenesis-relevant genes in human PMN, as de-
lineated by the RT-PCR technique. RT-PCR analyses of RNA ob-
tained from freshly isolated PMN, positive control or negative con-
trol (without template) were performed using specifi c primer sets 
and amplifi cation protocols as shown in table 2. The specifi c PCR-
DNA fragments were separated by agarose gel electrophoresis and 
visualized by ethidium bromide staining under UV light. We were 
also able to detect the expression of hepatocyte growth factor in 
human PMN using the RT-PCR technique (data not shown) which 
was not included in the microarray analysis. Three different prim-
er sets for VE-cadherin were used which all gave a positive result 
in human umbilical endothelial cells used as control. However, all 
three primer sets failed to amplify a VE-cadherin-specifi c fragment 
in human PMN (results for primer set VE-cadherin 1  are shown in 
table 2). M = marker. All results are representative of three inde-
pendent experiments. 
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wound healing process of CD18–/– animals was associ-
ated with an impairment of neovascularization within the 
granulation tissue suggesting a role of PMN in infl amma-
tion-mediated angiogenesis. 
 Discussion 
 Neovascularization by sprouting angiogenesis is criti-
cal for wound healing and repair. We have recently shown 
that PMN have the ability to directly induce angiogenesis 
in vitro suggesting a role of these cells for the induction 
of infl ammation-mediated angiogenesis  [16] . In order to 
delineate the molecular basis of this effect, the present 
study was undertaken to identify angiogenesis-relevant 
genes in these cells. By means of the microarray tech-
nique, we detected the mRNA expression of 28 genes, 
including fi ve known cytokines, namely IL-8, GRO-  , 
TGF-  , TNF-  and VEGF  [1, 6, 14, 20, 21] . In addition, 
we identifi ed MDK, a novel chemokine, in human PMN. 
All of the detected cytokines have been reported to act as 
proangiogenic mediators. This is especially true for VEGF 
and IL-8  [7, 12, 13, 16] , but also for GRO-  , TGF-  and 
TNF-  which have been demonstrated to serve as proan-
giogenic factors in different models  [15, 22, 23] . 
 The newly identifi ed cytokine MDK has been reported 
to induce the mobilization of intracellular calcium by a 
G protein-coupled mechanism and it induces chemotax-
is of human PMN  [24, 25] . In vivo evidence for a role of 
MDK in PMN infi ltration was demonstrated in a study 
using MDK-defi cient mice, in which the numbers of in-
fi ltrating neutrophils were reduced compared with wild-
 Fig. 3. Diminished vascularization of wound beds in CD18–/– 
mice. Cryosections of wound sites from CD18–/– and wild-type 
mice (CD18+/+) at day 5 after induction of injury. Immunofl uo-
rescence staining was performed with the rat anti-mouse CD31 
monoclonal antibody and a secondary cyanine 2-conjugated anti-
body.  a Sections showing the most signifi cant differences of CD31 
staining in each cohort (n = 4) are shown. The broken line indicates 
the border between eschar (esc) and mesenchymal restoration tissue 
(dermis). Scale bar = 200   m.  b Vessels staining positive for CD31 
were counted in each high-power fi eld. There was no difference in 
the vessel density of uninjured skin surrounding the wounds be-
tween CD18–/– and wild-type mice (data not shown). Similar re-
sults were obtained from three independent investigators. Bars in-
dicate the media of each cohort. ** p  ! 0.005. 
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type control animals in a model of renal ischemic reper-
fusion injury  [26] . Moreover, MDK has been found to 
induce angiogenesis in the rabbit corneal assay  [27] . Sim-
ilar studies have demonstrated a role of MDK in tumor 
progression by promoting angiogenesis in bladder cancer 
 [28] , and MDK expression has been shown to correlate 
with the poor outcome of patients with invasive cancers 
 [29] , suggesting that MDK acts as an activator of tumor 
angiogenesis. As we have identifi ed MDK expression in 
human PMN, it suggests a novel role of this chemokine 
in infl ammation-mediated angiogenesis. 
 Beside the expression of HIF-1  which is well known 
to induce for example VEGF  [30, 31] , we detected the 
expression of two novel angiogenesis-relevant transcrip-
tion factors in human PMN, namely erb-B2 and ets-1. 
The tyrosine kinase  erb-B2 acts as a transcriptional acti-
vator of the Cox-2 promotor  [32] , which upregulates 
VEGF expression via prostaglandin E 2 -mediated HIF-1  
induction  [31] . The transcription factor ets-1 is a target 
gene of HIF-1   [31] and induces the expression of differ-
ent MMPs, including MMP-9  [33] . MMP-9 is expressed 
by human PMN  [34] , activates TGF-  1   [35] and pro-
motes angiogenesis by degrading extracellular matrix 
proteins  [36] . Moreover, ets-1 stimulates angiogenesis by 
upregulating the expression of uPA  [37] . This protease is 
expressed by PMN  [38] and is known to activate TGF-  
and MMP-9 by proteolytic cleavage  [35, 36] . 
 In addition to T  RI  [39] , we identifi ed T  RII and 
T  RIII in human PMN, the latter of which is induced 
by HIF-1   [31] . This is of interest because low doses of 
TGF-  were found to promote angiogenesis  [40] , and 
mice defi cient in T  RI, T  RII or T  RIII show severe 
defects in vasculogenesis and/or angiogenesis  [41] . As 
TGF-  induces the expression of VEGF, MMP-2 and 
MMP-9 in fi broblasts, endothelial cells and human pros-
tate cancer cell lines  [42, 43] , the presence of the full set 
of TGF-  receptors in PMN suggests a putative role of 
TGF-  1  signaling in activating the proangiogenic poten-
tial of this cell type. 
 We confi rmed the expression of different adhesion 
molecules in human PMN, namely   5 -integrin,   3 -integ-
rin and platelet endothelial cell adhesion molecule 
(PECAM)  [44–46] . Although their endothelial expression 
is known to be critical for angiogenesis, their putative an-
giogenic role in PMN is rather questionable. Moreover, 
we detected the known factor THBS-1  [47] and identifi ed 
the expression of THBS-3 in human PMN. As THBS are 
known to inhibit angiogenesis  [48] , this fi nding suggests 
that PMN may also have an antiangiogenic potential. 
Moreover, we detected the expression of VE-cadherin in 
PMN using the microarray technique. Although three dif-
ferent primer sets were used, we were unable to reproduce 
this fi nding by the RT-PCR technique, suggesting that in 
this case, the microarray gave a false-positive result. 
 Among the angiogenesis-relevant enzymes, we detect-
ed the expression of four known proteins, i.e. Cox-2, 
HPSE, MMP-9 and uPA, in human PMN  [34, 38, 49, 50] . 
MMP-9 plays a prominent role in angiogenesis  [51] , but 
recent evidence also suggests an involvement of Cox-2 in 
this process. Accordingly, different nonsteroidal anti-in-
fl ammatory drugs acting selectively on Cox-2 were found 
to downregulate angiogenesis in a broad spectrum of dif-
ferent angiogenesis models leading to the identifi cation 
of Cox-2 as a target for tumor angiogenesis  [52] . As hu-
man PMN express erbB-2 which serves as an activator of 
the Cox-2 promoter  [32] , this fi nding may provide a new 
aspect for the induction of this enzyme in PMN .  Further-
more, we confi rmed the expression of CHGA, a member 
of the granin family of acidic secretory proteins, in human 
PMN  [53] and detected the expression of ephrin B2 and 
ephrin A2, ligands of ephrin receptor tyrosine kinases. 
Although the endothelial expression of ephrins and their 
receptors plays a role in angiogenesis  [54] , their putative 
function in PMN-mediated angiogenesis is elusive. More-
over, we demonstrated the expression of restin, a 22-kDa 
fragment of human collagen XV with homology to the 
angiogenesis inhibitor endostatin, which inhibits migra-
tion of endothelial cells  [55] . We also detected the expres-
sion of TIMP-1 and TIMP-2 which have been reported 
to serve as inhibitors of angiogenesis  [56, 57] . Thus, we 
found a total of four antiangiogenic factors (THBS-3, res-
tin, TIMP-1 and TIMP-2), which may imply that PMN 
not only possess proangiogenic but also antiangiogenic 
activity. However, TGF-  signaling downregulates TIMP 
expression  [35] , and the activation of Cox-2 has been 
 recently shown to suppress p53  [58] . As p53 induces 
the angiogenesis inhibitor THBS-1 and downregulates 
HIF-1   [31, 59] , the activation of PMN, which leads to 
the induction of Cox-2 activity, may shift the balance be-
tween the pro- and antiangiogenic activities of human 
PMN towards the proangiogenic potential. 
 Accordingly, activated human PMN have been shown 
to directly induce angiogenesis in vitro  [16] , arguing for 
a role of these cells in orchestrating the initiation of in-
fl ammation-mediated neovascularization during wound 
repair and tissue remodeling. In contrast to the extravasa-
tion of monocytes and lymphocytes, PMN infi ltration of 
several tissues strictly depends on leukocyte adhesion 
molecules of the   2 -integrin family (CD11/CD18). This 
is especially true for thioglycollate-induced peritonitis, 
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infl amed cremaster muscle and wounded skin  [17, 60] . 
Accordingly, PMN accumulation at sites of lesion has 
been shown to be severely compromised in these models 
 [17, 60] . We now present evidence that the impairment 
of PMN infi ltration in the absence of CD18 was accom-
panied by a reduction in infl ammation-mediated angio-
genesis in a skin model of wound healing which provides 
further evidence for a role of PMN in the induction of 
infl ammation-mediated angiogenesis. 
 The present fi ndings strongly suggest that not only one, 
but a variety of different factors may be involved in PMN-
mediated generation of functional vessels in vivo.  Figure 
4 gives an overview of these factors and their putative 
cross-talk, but it has been taken into consideration that 
the interpretation of the present data is limited by the 
measurement of gene expression at the mRNA level. 
Thus, further investigations are required to prove the 
functional impact of the factors identifi ed. To date, vari-
ous proangiogenic approaches are studied in clinical trials 
 [61] , but it seems to be a rather optimistic view that the 
in vivo application of one single factor can induce the 
formation of functional vessels and an intact microcircu-
lation in vivo. As tumor vessels are highly disorganized 
and show an abnormal microcirculation  [61] , it is also 
questionable whether the identifi cation of the factors re-
sponsible for the induction of tumor angiogenesis can 
provide insight into the mechanisms that are required for 
the generation of  functional microvascular networks in 
physiological settings; however, infl ammation-mediated 
angiogenesis represents a rare example of functional an-
giogenesis in the adult. Therefore, the identifi cation of the 
proangiogenic factors expressed in human PMN may 
help to unravel the requirements for sustained and func-
tional angiogenesis in vivo. 
 Acknowledgements 
 The expert technical assistance of Mrs. Manuela Haberl and 
Mrs. Adelheid Hainzl is acknowledged. This study was supported 
by Deutsche Forschungsgemeinschaft (Wa 1048/1-1 and 1048/1-2, 
Scha 411/12-1 and SFB 497-C7, Collaborative Research Center, 
Ulm, Germany). 
 Fig. 4. Schematic overview of angiogenesis-relevant factors in hu-
man PMN and their putative cross-talk. Dotted line: activation by 
proteolytic cleavage. 
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